Vera Therapeutics: Hold Rating Based On Potential For Atacicept In IgAN (Rating Downgrade)

Terry ChrisomalisInvesting Group LeaderFollow5ShareSavePlay(15min)CommentsSummaryVera Therapeutics is downgraded from 'Strong Buy' to 'Hold' due to intensifying competition in the IgAN space.VERA's atacicept met the primary endpoint in the phase 3 ORIGIN trial, enabling a BLA submission and Priority Review with a PDUFA date of July 7, 2026.Competitive risks are heightened by Otsuka's VOYXACT, which shows superior proteinuria reduction and more convenient dosing.VERA maintains strong liquidity with $779M pro forma cash and additional non-dilutive capital but faces pivotal eGFR data risk in 2027.Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Nacer HA/iStock via Getty Images The last time I spoke about Vera Therapeutics, Inc. (VERA), it was in a Seeking Alpha article entitled "Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN PatientsThis article was written byTerry Chrisomalis14.76K FollowersFollowTerry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare. He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.